Pleural Diseases – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Pleural Diseases Market Outlook

Thelansis’s “Pleural Diseases Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pleural Diseases treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pleural Diseases Overview

Pleural diseases encompass a range of conditions affecting the pleura, the tissue enveloping the lungs and lining the chest cavity. This tissue consists of two layers separated by a thin space known as the pleural space. Pleurisy, pleural effusion, and pneumothorax are the primary pleural disorders. While chest pain, shortness of breath, and coughing are common symptoms across these disorders, treatment approaches vary based on the specific type and severity. Biopsies involve extracting a sample from the pleura to examine for signs of disease. Blood tests are conducted to assess for underlying illnesses that may elevate the risk of pleurisy or other pleural disorders. Lung imaging tests, such as chest MRI or X-ray, are utilized to detect the presence of fluid or air in the pleural space and other potential causes of pleural disorders such as pneumonia, fractured ribs, or lung tumors. Infections in the pleural space or lung may necessitate antibiotics, antifungals, or antiparasitic medications. The thoracentesis procedure is also employed to obtain a sample of pleural fluid for diagnostic testing. Corticosteroids are used to alleviate inflammation, while morphine and nonsteroidal anti-inflammatory drugs (NSAIDs) can manage associated symptoms.

• Pleural diseases incidence is 7.4/100,000 (men) and 1.2/100,000 (women) annually in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: